SCH 412499: Biodistribution and safety of an adenovirus containing P21 WAF-1/CIP-1 following subconjunctival injection in cynomolgus monkeys

Cutaneous and Ocular Toxicology

Volumn 26, Issue 2, 2007, Pages 83-105

  Veneziale, Robert W ^a   Bral, Christopher M ^a   Sinha, Dinesh P ^a   Watkins, Robert W ^a   Cartwright, Mark E ^a   Rosenblum, Irwin Y ^a   Treinen, Kimberley A ^a   Kishnani, Narendra S ^a   Nelson, Joyce ^b   Chen, Zoe ^a   Faha, Barbara ^a   Maneval, D ^a   Munger, Robert J ^c   Cai, Xiao Yan ^a   Cullen, Constance ^a   Arezzo, Joseph C ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

^c Animal Ophthalmology Clinic   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adenovirus; Choroid; Fistula patency; Gene therapy; Glaucoma; Inflammation; Monkey; P21WAF 1 CIP 1; Subconjunctival injection; Toxicity; Trabeculectomy; Wound healing

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; SCH 412499; UNCLASSIFIED DRUG;

ADENOVIRUS; ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; CELL INFILTRATION; CHOROID; CONJUNCTIVA; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SAFETY; ELECTRORETINOGRAM; EVOKED VISUAL RESPONSE; EYE SWELLING; FEMALE; GLAUCOMA SURGERY; MALE; MONKEY; NONHUMAN; POSTOPERATIVE CARE; SINGLE DRUG DOSE; TRABECULECTOMY;

ADENOVIRIDAE; ANESTHESIA; ANIMALS; BLOOD PRESSURE; CONJUNCTIVA; CONJUNCTIVITIS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ELECTRORETINOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVOKED POTENTIALS, VISUAL; EYE; FEMALE; GENE THERAPY; GLAUCOMA DRAINAGE IMPLANTS; HEART RATE; INJECTIONS; MACACA FASCICULARIS; MALE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; TRABECULAR MESHWORK; WOUND HEALING;

ADENOVIRIDAE; FISTULA; MACACA FASCICULARIS;

EID: 34347391234     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.1080/15569520701212167     Document Type: Article

References (43)

1. Quigley HA, Enger C, Katz J, Sommer A, Scott R, Gilbert D. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol 1994(May); 112(5):644-649.
2. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000(Oct); 130(4):429-440.
3. Obstbaum SA, Cioffi GA, Krieglstein GK, Fennerty MB, Alm A, Araie M, Carassa RG, Hitchings RA, Kaufman PL, Kitazawa Y, Pongpun PR, Susanna R, Wax MB, Zimmerman TJ. Gold standard medical therapy for glaucoma: Defining the criteria identifying measures for an evidence-based analysis. Clin Ther 2004; 26(12):2102-2120.
4. Marquis RE, Whitson JT, Management of glaucoma: Focus on pharmacological therapy. Drugs Aging 2005; 22(11):1-21.
5. Lichter PR, Musach DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills RP, and the CIGTS Study Group. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001(Nov); 108(11):1943-1953.
6. Hitchings RA, Migdal CS, Wormald R, Poinooswamy D, Fitzke F. The primary treatment trial: Changes in the visual field analysis by computer-assisted perimetry. Eye 1994; 8(Pt 1):117-120.
7. Jay JL, Allan D. The benefit of early trabeculectomy versus conventional management in primary open angle glaucoma relative to severity of disease. Eye 1989; 3(Pt 5):528-535.
8. Daniels JT, Occleston NL, Crowston JG, Cordeiro MF, Alexander RA, Wilkins M, Porter R, Brown R, Khaw PT. Understanding and controlling the scarring response: The contribution of histology and microscopy. Microsc Res Tech 1998(Sep 1); 42(5):317-333.
9. Skuta GL, Parrish RK, 2nd. Wound healing in glaucoma filtering surgery. Surv Ophthalmol 1987(Nov-Dec); 32(3):149-170.
10. Joshi AB, Parrish RK, 2nd, Feuer WF. 2002 survey of the American Glaucoma Society: practice preferences for glaucoma surgery and antifibrotic use. J Glaucoma 2005(Apr); 14(2):172-174.
11. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003(May-Jun); 48(3):314-346.
12. Wormald R, Wilkins MR, Bunce C. Post-operative 5-Fluorouracil for glaucoma surgery. Cochrane Database Syst Rev 2001; (3):CD001132.
13. Bindlish R, Condon GP, Schlosser JD, D'Antonio J, Lauer KB, Lehrer R. Efficacy and safety of mitomycin-C in primary trabeculectomy: Five-year follow-up. Ophthalmology 2002(Jul); 109(7):1336-1341.
14. DeBry PW, Perkins TW, Heatley G, Kaufman P, Brumback LC. Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. Arch Ophthalmol 2002(Mar); 120(3):297-300.
15. WuDunn D, Cantor LB, Palanca-Capistrano AM, Hoop J, Alvi NP, Finley C, Lakhani V, Burnstein A, Knotts SL. A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy. Am J Ophthalmol 2002(Oct); 134(4):521-528.
16. Edmunds B, Thompson JR, Salmon JF, Wormald RP. The national survey of trabeculectomy, III. Early and late complications. Eye 2002(May); 16(3):297-303.
17. Loane ME, Galanopoulos A. The surgical management of leaking filtering blebs. Curr Opin Ophthalmol 1999(Apr); 10(2):121-125.
18. Wilkins M, Indar A, Wormald R, Wilkins M. Intra-operative Mitomycin C for glaucoma surgery. Cochrane Database Syst Rev 2005(Oct 19); (4):CD002897.
19. Perkins TW, Faha B, Ni M, Kiland JA, Poulsen G, Antelman D, Atencio I, Shinoda J, Sinha D, Brumback L, Maneval D, Kaufman PL, Nickells RW. Adenovirus-mediated gene therapy using human p21WAF-1/Cip-1 to prevent wound healing in a rabbit model of glaucoma filtration surgery. Arch Ophthalmol 2002(Jul); 120(7):941-949.
20. Heatley G, Kiland J, Faha B, Seeman J, Schlamp CL, Dawson DG, Gleiser J, Maneval D, Kaufman PL, Nickells RW. Gene therapy using p21WAF-1/Cip-1 to modulate wound healing after glaucoma trabeculectomy surgery in a primate model of ocular hypertension. Gene Ther 2004(Jun); 11(12):949-955.
21. Wen SF, Chen Z, Nery J, Faha B. Characterization of adenovirus p21 gene transfer, biodistribution, and immune response after local ocular delivery in New Zealand white rabbits. Exp Eye Res 2003(Sep); 77(3):355-365.
22. The Nonclinical Laboratory Studies Good Laboratory Practice Regulations issued by the U.S. Food and Drug Administration (Title 21 of the Code of Federal Regulations, Part 58); effective June 20, 1979.
23. The OECD Principles on Good Laboratory Practice [C(97)186/Final], effective 1997.
24. The Japanese Good Laboratory Practice Standards for Safety Studies on Drugs (Ordinance No. 21 of the Pharmaceutical Affairs Bureau, Ministry of Health, Labor and Welfare, Japan; effective April 1, 1997).
25. WAF/Cip1 for potential use in ocular gene therapy. Preclinica 2003 (Sept/Oct) 1(4):187-197.
26. Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt MT, Huang WM, Johnson DE, Anderson SC, Wen SF, Bookstein H, Shepard M, Gregory RJ. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994(Sep); 5(9):1079-1088.
27. Hackett R, McDonald T. Assessing ocular irritation. In: Marzulli FN, Maibach HI, eds. Dermatotoxicology, 5th ed. Washington, D.C.: Taylor and Francis; 1996:557-567.
28. Spence S, Soper K, Hoe C-M, Coleman J. The heart rate-corrected QT interval of conscious beagle dogs: A formula based on analysis of covariance. Toxicol Sci 1998(Oct); 45(2):247-258.
29. Haynes WL, Alward WL. Control of intraocular pressure after trabeculectomy. Surv Ophthalmol 1999(Jan-Feb); 43(4):345-355.
30. Gu D, Atencio I, Kang DW, Looper LD, Ahmed CM, Levy A, Maneval D, Zepeda ML. Recombinant adenovirus-p21 attenuates proliferative responses associated with excessive scarring. Wound Repair Regen 2005(Sep-Oct); 13(5):480-490.
31. Morrissey RE, Horvath C, Snyder EA, Patrick J, Collins N, Evans E, MacDonald JS. Porcine toxicology studies of SCH 58500, an adenoviral vector for the p53 gene. Toxicol Sci 2002(Feb); 65(2):256-265.
32. Morrissey RE, Horvath C, Snyder EA, Patrick J, MacDonald JS. Rodent nonclinical safety evaluation studies of SCH 58500, an adenoviral vector for the p53 gene. Toxicol Sci 2002(Feb); 65(2):266-275.
33. Rasmussen HS, Smith AC, Durham RJ, Rasmussen CS, Bee WH, Wills MC, Munger RJ, Tomlinson MJ, MacGill R, King CR, McVey D, Wei LL. Safety of intravitreal adenoviral gene therapy containing human pigment epithelium-derived factor transgene in monkeys. Preclinica 2003(Mar/Apr); 77-85.
34. Stout T, Klein M, Holz E, Gupta A, Saperstein D, Wei LL, Ray A, Kessler P, Frank RN, Campochiaro PA. AdPEDF therapy for subfoveal choroidal neovascularization (CNV): Preliminary phase I results. Molecular Therapy 2004(May); 9(Suppl 1):S408.
35. Borras T, Brandt CR, Nickells R, Ritch R. Gene therapy for glaucoma: Treating a multifaceted, chronic disease. Invest Ophthalmol Vis Sci 2002(Aug); 43(8):2513-2518.
36. Weiter JJ, Roh S. Viral infections of the choroid and retina. Infect Dis Clin North Am 1992(Dec); 6(4):875-891.
37. Forrester JV, McMenamin PG. Immunopathogenic mechanisms in intraocular inflammation. Chem Immunol 1999; 73:159-185.
38. Jo N, Wu GS, Rao NA. Upregulation of chemokine expression in the retinal vasculature in ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 2003(Sep); 44(9):4054-4060.
39. van der Woerdt A. Management of intraocular inflammatory disease. Clin Tech Small Anim Pract 2001(Feb); 16(1):58-61.
40. Chan CC, Li Q. Immunopathology of uveitis. Br J Ophthalmol 1998(Jan); 82(1):91-96.
41. Rao NA. Mechanisms of inflammatory response in sympathetic ophthalmia and VKH syndrome. Eye 1997; 11(Pt 2):213-216.
42. Magone MT, Whitcup SM. Mechanisms of intraocular inflammation. Chem Immunol 1999; 73:90-119.
43. Priem HA, Oosterhuis JA. Birdshot chorioretinopathy: Clinical characteristics and evolution. Br J Ophthalmol 1988(Sep); 72(9):646-659.